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A B S T R A C T
The prevalence of diabetes mellitus increased during the last century and it is estimated 
that 45% of the patients are not diagnosed. In South America the prevalence of diabetes and 
chronic kidney disease (CKD) increased, with a great disparity among the countries with 
respect to access to dialysis. In Ecuador it is one of the main causes of mortality, principally 
in the provinces located on the coast of the Pacific Ocean. The greatest single cause of 
beginning dialysis is diabetic nephropathy (DN). Even using the best therapeutic options 
for DN, the residual risk of proteinuria and of terminal CKD remains high. In this review 
we indicate the importance of the problem globally and in our region. We analyse relevant 
cellular and molecular studies that illustrate the crucial significance of glomerular events 
in DN development and evolution and in insulin resistance. We include basic anatomical, 
pathophysiological and clinical concepts, with special attention to the role of angiogenic 
factors such as the vascular endothelial growth factor (VEGF-A) and their relationship to 
the insulin receptor, endothelial isoform of nitric oxide synthase (eNOS) and angiopoietins. 
We also propose various pathways that have therapeutic potential in our opinion. Greater 
in-depth study of VEGF-A and angiopoietins, the state of glomerular VEGF resistance, the 
relationship of VEGF receptor 2/nephrin, VEGF/insulin receptors/nephrin and the relationship 
of VEGF/eNOS-NO at glomerular level could provide solutions to the pressing world problem 
of DN and generate new treatment alternatives.
© 2015 Sociedad Española de Nefrología. Published by ELSEVIER ESPAÑA, SLU. Published 
under the terms of the CC BY-NC-ND Licence(http://creativecommons.org/licenses/
by-nc-nd/4.0).
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Issue relevance
The prevalence of diabetes mellitus has increased worldwide 
since the last century1. In adults aged between 20 and 79 years 
of age, its prevalence reaches 8%1. Diabetes spreads through 
rich and poor countries, but it is prevalent in vulnerable 
groups and lower-income regions of the world. Territories 
showing the highest numbers of affected individuals are: 
China, India, the United States, Brazil and Russia1. This situ-
ation is associated with greater urbanisation, low socioeco-
nomic level, inequality, increased life expectancy and 
population density, ethnic factors, nutrition, physical inac-
tivity, and being overweight1,2. In Spain, a diabetes prevalence 
rate of 13.8% was reported, while 6.0% had not yet been diag-
nosed3. Recent estimates suggest that worldwide prevalence 
will have doubled by 2035, while in our region, South America 
and Central America, it will have increased to 9.8%1,2. In addi-
tion, 45.5% of individuals with diabetes will not be diagnosed 
with the disease1,2. 
In the urban population located on the coasts of our region, 
diabetes prevalence is higher than in the mountains or the 
jungle, and the same happens with people who move from the 
rural to the urban environment1-2. Moreover, native popula-
tions are particularly vulnerable due to the change in lifestyle, 
marginalisation and lower exposure to health care systems2. 
In Ecuador, the prevalence of diabetes is 6%, and in 2010 it was 
the second cause of mortality2,4,5. In the provinces of Guayas, 
Los Ríos and Manabí, located on the Pacific coast, the mortality 
rate due to diabetes and industrialised food consumption is 
higher; meanwhile, in the Amazon, natural food-based nutri-
tion predominates and the rate is lower6 (Figure 1).
Kidney disease caused by diabetes is called diabetic 
nephropathy (DN). About 30% of patients with diabetes develop 
DN7,8. Such disease is the main cause of chronic kidney disease 
(CKD) and of admission to dialysis7-11. The increase in adult 
diabetes has been recorded in the last few decades, and CKD 
affects 10% to 16% of adults, which constitutes a serious 
worldwide problem7-11. In South America, the prevalence of 
diabetes and end-stage CKD (ECKD) has increased in recent 
decades, and access to dialysis varies greatly among these 
countries9-11. In Ecuador, the prevalence of patients who 
received renal function replacement therapy in 2010 was 406 
individuals per one million inhabitants11. On the other hand, 
the renin-angiotensin-aldosterone system (RAAS) inhibitors 
constitute the best therapeutic option for DN, but the residual 
risk of ECKD continues to be high and the association of these 
drugs was related to hyperkalemia and acute kidney failure 
(AKF)12-13. The search for new therapeutic alternatives is nec-
essary.
Population studies raise awareness of the problem, while 
the knowledge generated in research laboratories expand our 
understanding of the biological events that occur in individ-
uals. In this review, we will include anatomical and patho-
physiological concepts that reveal the crucial importance of 
events occurring at the glomerular level. In addition, we will 
analyse the role played by the vascular endothelial growth 
factor (VEGF-A) and its relationships with nitric oxide (NO), 
Aspectos celulares y moleculares de la nefropatía diabética, rol del 
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R E S U M E N
La prevalencia de diabetes mellitus aumentó en el último siglo y se estima que el 45% de 
los pacientes, no estarían diagnosticados. En Sudamérica la prevalencia de diabetes y de 
enfermedad renal crónica (ERC) incrementó, existiendo gran disparidad entre los países 
respecto al acceso a diálisis. En Ecuador es una de las principales causas de mortalidad, 
principalmente en las provincias ubicadas en la costa del océano Pacífico. La mayor causa 
aislada de ingreso a diálisis es la nefropatía diabética (ND). Aun utilizando las mejores opciones 
terapéuticas para la ND, el riesgo residual de proteinuria y de ERC terminal permanece elevado. 
En esta revisión describimos la importancia del problema en el mundo y en nuestra región. 
Analizamos estudios moleculares y celulares relevantes que indican la crucial importancia de 
eventos glomerulares en el desarrollo y en la evolución de la ND y en la insulinorresistencia. 
Incluimos conceptos anatómicos, fisiopatológicos y clínicos básicos, desarrollando especial 
énfasis en el rol de factores angiogénicos como el factor de crecimiento vascular endotelial 
(VEGF-A) y su relación con el receptor de insulina, la sintasa endotelial de óxido nítrico-óxido 
nítrico (eNOS) y las angiopoietinas. En el transcurso del texto proponemos diversas vías, que 
a nuestro entender tienen potencial terapéutico. Profundizar en el estudio del VEGF-A y las 
angiopoietinas, el estado de VEGF resistencia glomerular, la relación del receptor 2 de VEGF/
nefrina, VEGF/receptores de insulina/nefrina, la relación VEGF/eNOS-ON a nivel glomerular 
podría aportar soluciones al acuciante problema de la ND en el mundo y generar nuevas 
alternativas de tratamiento.
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65 years, male gender, smoking habit, family history and 
Hispanic or Afro-American origin7,8. Familial clustering was 
reported in populations with different ancestors, especially 
in Pima Indians and Afro-Americans16. Mooyaart et al. found 
24 genetic variations associated with DN17. Epigenetic mech-
anisms were also implied8,18. For example, chronic hypergly-
caemia, without altering the nucleotide sequence, may 
modify DNA or methylate histones associated with DNA18. 
However, the significance of these findings on the develop-
ment of DN has not been determined yet.
Many factors were implied in DN pathophysiology, such 
as: glucose, glucose receptors, VEGF-A, NO, reactive oxygen 
species (ROS), transforming growth factor beta (TGF-Beta), 
RAAS, kinin-kallikrein system, mammalian target of rapa-
mycin, inflammation, tumour necrosis factor alpha, adi-
ponectin, advanced glycation end products and receptors 
thereof, mitochondr ial oxidat ive stress and micro-
RNA7,8,15,19,20-22.
From the pathologic point of view, type 1 and type 2 dia-
betes induce common kidney lesions. These lesions were 
characterised in type 1 diabetes7,8,15,23-26. In type 2 diabetes, 
the kidney histology and course have special features, asso-
ciated with comorbidities such as HTN, vascular diseases, 
ageing and obesity7,8,23-24. Five years after diabetes diagnosis, 
there is hyperfiltration, microalbuminuria, glomerulomegaly, 
glomerular basal membrane (GBM) thickening and alteration 
of podocytes26. Subsequently, the extracellular matrix (ECM) 
is deposited in the mesangium. Approximately ten years later, 
proteinuria and HTN are evident, and GF becomes progres-
sively impaired7,23,24,26. Within a period of 20 to 25 years, scle-
rosis is advanced, there is tubulointerstitial fibrosis and CKD 
progresses to end-stage phases7,24-26.
Meanwhile, the glomeruli, tubules, interstitium and renal 
arteries are modified by the diabetic environment. Glomerular 
changes involve the glomerular filtration barrier (GFB), ECM, 
and the main cells composing it (podocytes, endothelial cells 
and mesangial cells)7,16,19-21-25. In addition, it prevents the 
abnormal passage of plasma protein based on size and load, 
and its alteration was associated with proteinuria7,15,19,20,25. 
The GFB is composed of podocytes, GBM, and the endothelium 
(Figure 2). Podocytes are markedly differentiated epithelial 
cells, with a large cell body, and primary and secondary 
extensions connected by slit diaphragms (SD)15,19,20. The SD 
is permeable to water and small solutes, but it is selective to 
large molecule passage, which is a key factor in GFB perme-
ability25. Moreover, it is composed of a protein complex, where 
nephrin plays an important role7,15,19,20. On the apical side, 
podocytes float within the urinary space, while on the baso-
lateral side, they make contact with the GBM. Podocyte cyto-
skeleton proteins are related to GBM proteins through 
integrins and dystroglycans15,20,25. The GBM is mainly com-
posed of proteins, such as collagen IV and laminins15,25. The 
fenestrated endothelium, covered by glycocalyx, is the inner 
most layer of the GFB7,15,21,25. Diabetes alters the three layers 
that make up the GFB. Among the early changes, neoangio-
genesis in the glomerular vascular pole and loss of endothe-
lial fenestrations have been described7,16,22,23. The GBM shows 
an increased thickness due to protein exchange alter-
ations7,15,19,20,25. In podocytes, f lattening, hypertrophy, 
the insulin receptor and angiopoietins. Finally, we will con-
sider basic aspects and the analyses of recently published 
molecular and cellular studies.
Anatomical and pathophysiological aspects of DN
Diabetes involves functional and structural kidney alterations 
that induce proteinuria at variable magnitudes, ranging from 
micrograms to several grams per day7,8,13. The risk of devel-
oping ECKD is related to albumin urinary excretion, and early 
treatment with RAAS inhibitors is important due to the ben-
eficial renal and systemic effects7,8,13. DN is accompanied by 
persistent albumin urinary excretion or microalbuminuria, 
which is defined as the loss of urinary albumin ranging from 
20 to 199 μg/min or 30 to 299 mg/d on two different occasions 
and when the albumin/creatinine ratio is 30-299 mg/g in an 
isolated urine sample7,8. In type 1 diabetes, albumin urinary 
excretion should be quantified on an annual basis, from the 
fifth year following diagnosis onwards; in type 2 diabetes, 
given the difficulty to accurately state its onset, measurement 
is preferable from the moment the disease is diagnosed7,8. In 
one study, the prevalence of microalbuminuria in patients 
with type 2 diabetes was 24.9% after a ten-year follow-up14, 
but 30% of patients with type 2 diabetes and no microalbu-
minuria developed DN. It is also important to quantify glo-
merular filtration (GF), since some patients only show renal 
function impairment with no signs of proteinuria7,8. 
Considering that 85% of the patients with diabetes have type 
2 diabetes, better biomarkers are required7,8,13,14.
Risk factors contributing to the development of DN are 
hyperglycaemia, hypertension (HTN), dyslipidaemia, age over 
Figure 1 – In Ecuador, mortality caused by diabetes mellitus 
was higher in the provinces of Guayas, Los Ríos and Manabí, 
located on the Pacific coast. Map shows the mortality rate 
due to diabetes mellitus (deaths/100,000 individuals per year, 
INEC [Instituto Nacional de Estadísticas y Censos - National 
Institute of Statistics and Census of Ecuador] 2011). This figure 
is part of a figure originally published by Neira-Mosquera et 
al.6, with minor modifications (authorised reproduction).
Mortality due to Diabetes Mellitus
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The role of VEGF-A in DN
VEGF-A is a potent angiogenic factor related to normal and 
pathological angiogenesis. It promotes the proliferation, dif-
ferentiation and migration of endothelial cells; it induces 
vasodilation and increases vascular permeability15,19,20,27. It 
plays an important role in kidney development; in the adult 
kidney, it is secreted by podocytes and is essential for the 
maintenance of the GFB15. It acts through tyrosine-kinase 
receptors, which are known as VEGF receptor 1 and 2 (VEGFR1 
and 2)15,27. VEGFR2 is expressed in endothelial cells and podo-
cytes; it is related to the most important signals of VEGF-A15,27. 
Two co-receptors called neuropilins 1 and 2 amplify the 
VEGFR2 signal15.27.
There is evidence that glucose directly and indirectly stim-
ulates VEGF-A expression in podocytes through angiotensin 
II and TGF-Beta15,19,20. Glucose plays a very important role in 
DN pathophysiogenesis. Glycaemic control reduces DN pro-
gression and induces reversion of proteinuria and advanced 
histological lesions28-32. In a 30-year follow-up study, protein-
detachment and apoptosis are observed in the early stages, 
while later podocytopenia is observed7,15,19,20.
Recently published articles that relate VEGF-A to glomer-
ular proteins involved in human and experimental DN patho-
physiogenesis are analysed below. Throughout the text, we 
will suggest several pathways which may be used to generate 
new therapeutic tools (Table 1).
Tubular poleA B
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CL
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Vascular pole
Podocytes
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Endothelium
Figure 2 – Schematic representation of the glomerulus, the glomerular filtration barrier (GFB) composed of 
podocytes (P), the glomerular basal membrane (GBM), and the endothelium. Plasma ultrafiltration passes through the 
GFB (black arrow) to reach the urinary space (US). Podocytes (green) make contact with several glomerular capillaries 
(represented as red circles) and the intraglomerular mesangium (M). The GBM (black line) wraps the capillaries and 
surrounds the mesangium. The glomerular endothelium is represented by a discontinuous light-blue line, located 
between the capillary lumen (CL) and the GBM, the vascular pole in the lower part of the glomerulus, the tubular pole in 
the upper part. B: Ultrastructure of the GFB observed with an electronic microscope: podocytes, GBM, slit diaphragm (SD) 
and fenestrated endothelium. Plasma ultrafiltration passes through the GFB (yellow arrow) from the capillary lumen (CL) 
towards the urinary space (US).
Table 1 – Glomerular pathways with therapeutic 
potential for DN
Stimulated pathways Inhibited pathways
TGF-Beta eNOS
CTGF VEGFR2 activity
VEGF-A Nephrin
Angiopoietin 2 Angiopoietin 1
Legend: TGF-Beta (transforming growth factor), CTGF (connective 
tissue growth factor), VEGF-A (vascular endothelial growth factor), 
eNOS (endothelial nitric oxide synthase) 
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a good marker of glomerular expression or DN severity. Urine 
and systemic VEGF-A levels were high in diabetic mice with 
and without glomerular VEGF overexpression34. Probably, 
within the diabetes context, urinary excretion of VEGF-A 
ref lects systemic levels, while hiding VEGF glomerular 
changes34. In short, these experiments suggest that glomer-
ular VEGF-A is a determining factor in DN, that VEGF overex-
pression in podocytes is dangerous, and that glucose directly 
and indirectly stimulates the VEGF-A signalling cascade in 
podocytes. In diabetes, urinary and systemic VEGF-A did not 
correlate with either glomerular VEGF expression or with the 
severity of glomerular lesions, which brings into question the 
use of VEGF-A as a DN biomarker.
Glomerular VEGF-A reduction was shown to generate GFB 
lesions, proteinuria and kidney failure in animals and 
humans42,43. Transgenic mice with silencing of VEGF-A in 
podocytes showed AKF, alteration of the three GFB layers and 
reduced integrin expression43. Some patients treated with 
anti-VEGF-A antibodies showed proteinuria, endothelial 
lesions and thrombotic microangiopathy42. This evidence 
suggests that VEGF-A released by podocytes is important for 
the maintenance of the function and the glomerular structure 
in the adult kidney. Whether glomerular VEGF-A expression 
control improves DN has not yet been determined, but there 
is evidence that shows contradictory results. Administration 
of anti-VEGF antibodies improved DN in rodents44. In exper-
iments conducted in mice, endostatin and tumstatin pre-
vented the development of DN due to a decrease in VEGF-A 
and angiopoietin 236. In contrast, diabetic mice with gene 
deletion of VEGF-A in podocytes showed proteinuria and 
severe diffuse glomerulosclerosis associated with endothelial 
injury and apoptosis42.
The evidence described herein suggests that close moni-
toring of glomerular VEGF-A levels in diabetes is required in 
order to avoid adding new lesions or worsening DN. Monitoring 
glomerular VEGF-A expression within very close margins may 
have a therapeutic potential, but the optimal concentrations 
and the right moment to perform such manipulation have not 
yet been defined.
VEGF-A relationships with insulin receptors, 
nephrin and ROS in DN
In DN, glomeruli with different lesion degrees coexist; VEGF-A 
expression and its signalling cascade have been related to 
glomerular changes37. In biopsies of patients with DN, there 
has been evidence of a higher VEGF expression in the glom-
eruli with lesions due to diabetes than in intact glomeruli37. 
However, VEGF-bound receptor expression was seen to be 
elevated in glomeruli with mild lesions and decreased in 
glomeruli with moderate or severe compromise37. A similar 
behaviour was observed with phosphorylation of serine/thre-
onine protein kinase, a protein located in the VEGF signalling 
cascade, which suggested that other factors would modulate 
VEGF/VEGFR activity37.
Podocytes express insulin receptors, whose activity 
depends on nephrin expression45,46. Insulin receptors are 
located in the SD, where podocytes express nephrin and 
uria, GF and HTN showed an improvement in patients with 
type 1 diabetes when there was better glycaemic control28. 
With a higher control of hyperglycaemia, GBM has shown less 
thickening29. Histological changes of advanced DN reverted 
10 years after pancreas transplantation30. Haraguchi et al. 
were able to revert nephrotic-range proteinuria and histolog-
ical lesions compatible with advanced DN after five years of 
intensive treatment of hyperglycaemia31. Treatment with 
bariatric surgeries administered to patients with type 2 dia-
betes and obesity improved GF and proteinuria, which was 
related to weight loss and decreased hyperglycaemia32.
Hyperglycaemia increases renin and angiotensinogen 
expression in mesangial cells20. Mesangial cells and podo-
cytes synthesise angiotensin II and express angiotensin 
receptors19,20. The increase in angiotensin II stimulates the 
expression of TGF-Beta, VEGF-A, connective tissue growth 
factor (CTGF), interleukin 6 and chemoattractant protein for 
monocytes-1 inducing expansion of the ECM and podocyte 
apoptosis7,15,19,20.
In addition, glucose increases TGF-Beta expression in 
mesangial cells and podocytes19. Active TGF-Beta induces GBM 
thickening and glomerulosclerosis through the VEGF and 
CTGF; the increase in VEGF-A inhibits TGF-Beta expression, in 
a negative feedback mechanism15,19,20. In contrast, the increase 
in VEGF-A in diabetes is associated with elevated TGF-Beta and 
CTGF, proliferation and build-up of proteins in the glomerular 
ECM15,19,20. TGF-Beta has been related to the proliferation of 
mesangial cells, diffuse nodular glomerulosclerosis and also 
fibrosis15,19,20. In transgenic mice with no TGF-Beta type 2 
receptor and the administration of anti-TGF-Beta antibodies 
prevented mesangial build-up and kidney function impair-
ment19,20. These antibodies represent a therapeutic hope for 
DN, but they are not available for human use yet19.
Glomerular VEGF-A modifications in DN
Starting from early DN stages, systemic and renal VEGF-A are 
elevated in humans and mice, VEGF-A has been associated 
with neoangigenesis15,21,22. RAAS, VEGF-A and nephrinuria 
were seen to be involved in this process15,19,20,22,33-38. Cultured 
podocytes and endothelial cells increased VEGF-A and 
VEGFR2 expression in response to the increase in glucose39-41. 
We showed that glomerular VEGF is a key factor for DN devel-
opment and progress33-34. Normoglycaemic mice with VEGF 
overexpression in podocytes developed glomerulomegaly, 
hyperfiltration, GBM thickening and podocyte lesion, which 
are changes similar to early DN33. In these transgenic mice, 
diabetes caused massive proteinuria, advanced nodular glo-
merulosclerosis and less nephrin expression34. Diabetic mice 
with no VEGF overexpression only showed mild diffuse glo-
merulosclerosis34. These experiments demoatrate that the 
increase in glomerular VEGF, irrespective of the diabetic envi-
ronment, generates identical changes to the early DN and that 
increasing glomerular VEGF speeds up DN progress to more 
advanced stages. In the absence of diabetes, the urinary 
VEGF-A was reported to be a good marker of VEGF glomerular 
expression and it correlated with proteinuria33. Contrarily, in 
to the diabetes context, VEGF-A has not been observed to be 
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lower angiopoietin 1 levels showed aberrant angiogenesis, 
hyperfiltration, glomerulomegaly and albuminuria, accom-
panied by VEGF-A and phosphorylated VEGFR2 overexpres-
sion. Alterations caused by reduced angiopoietin 1 were seen 
to be partially prevented by restoring its expression in podo-
cytes of transgenic mice36. These experiments show the 
importance of angiopoietins and their relationship with 
VEGF-A in DN pathophysiogenesis. Modification of protein 
expression at the glomerular level (by manipulating the cells 
that produce these proteins) is a therapeutic alternative36.
Relationship between VEGF-A and nitric 
oxide in DN
VEGF-A stimulates NO production by means of endothelial NO 
synthase (eNOS) activation15,35.50. The effects of VEGF-A on 
vasodilation and on the vascular permeability increase are 
mediated by the increase in eNOS-dependent NO15,27,35,50. 
Under normal conditions, VEGF-A induces eNOS activation and 
an increase in NO; this increase negatively regulates VEGF-A 
and CTGF, inhibiting ECM build-up15. In diabetes, this relation-
ship changes: the increase in VEGF-A coexists with lower eNOS 
activity, and there is VEGF-A and NO decoupling50. Along the 
lines of this theory, eNOS KO diabetic mice increased VEGF-A 
expression and developed severe DN50. We showed that VEGF 
overexpression in podocytes of eNOS KO mice, induced indis-
tinguishable changes of the advanced DN35. In the absence of 
diabetes, these transgenic mice developed proteinuria, kidney 
failure and nodular glomerulosclerosis35. This evidence sug-
gests that alterations in glomerular VEGF-A/NO-eNOS rela-
tionship are critical and very dangerous, highlighting these 
events and their relationship with VEGF-A as treatment targets 
at the glomerular level.
Endothelial NO deficiency secondary to reduced eNOS 
activity may also associate insulin resistance mechanisms 
with endothelial dysfunction47,48. Endothelial cells express 
insulin receptors. By means of eNOS activation, these recep-
tors control vascular tone by inducing vasodilation. For exam-
ple, in patients with diabetes there are alterations in eNOS 
activation, establishing a relationship between NO and endo-
thelial insulin resistance47-49. These findings suggest that 
VEGF-A and the glomerular NO/eNOS ratio may be implied in 
the insulin resistance status associated with prediabetes, 
diabetes and CKD.
Conclusions
Population studies reveal an increasing prevalence of type 2 
diabetes worldwide, which suggests that DN will become an 
even more serious problem. It is imperative to look for alter-
natives for the diagnosis, prevention and treatment of DN. 
Going further in the study of molecular pathways with ther-
apeutic potential, such as angiogenic factors, the glomerular 
VEGF resistance status, insulin resistance in podocytes, the 
VEGFR2/nephrin relationship, VEGF/insulin receptors /neph-
rin relationship, and the VEGF/NO-eNOS relationship, may 
provide solutions to the urgent problem of DN in the world.
VEGFR233,46. We have characterised the existing interaction 
between nephrin and VEGFR216. VEGF overexpression in 
podocytes was found to decrease nephrin expression and 
phosphorylation16,33. Hale et al. reported that insulin 
increases VEGF-A production in podocytes, both in humans 
and mice45. In transgenic mice, this VEGF-A increase was 
disrupted by insulin resistance, anticipating the development 
of podocyte lesions secondary to insulin resistance45. In 
patients with insulin resistance caused by diabetes and by 
other diseases, kidney alterations, such as hyperfiltration, 
proteinuria, modifications in FGB and mesangium were 
described47,48. Jointly, these findings suggest that VEGF, neph-
rin and insulin receptor may be related to DN and insulin 
resistance, thus constituting glomerular pathways suscepti-
ble to being modified.
Furthermore, oxidative stress secondary to hyperglycaemia 
may modify glycocalyx, increase ROS and advanced glycation 
end products, and alter the endothelium. In addition, protein 
kinase C (PKC) glomerular activation was associated with 
mesangial expansion, GBM thickening, endothelial dysfunc-
tion, cytokine and TGF-Beta activation7,15,21,40,41. Mima et al. 
described that hyperglycaemia alters nephrin phosphorylation 
in diabetic rats and cultured podocytes exposed to high con-
centrations of glucose49. Nephrin phosphorylation interrup-
tion was attributed to a “glomerular VEGF resistance” status 
related to PKC activation49. The VEGF signalling cascade in 
podocytes and endothelial cells was selectively inhibited by 
hyperglycaemia49. The increase in glucose and diabetes would 
cause higher podocyte apoptosis and endothelial dysfunction, 
partly due to a higher activation of mitogen-activated protein 
kinase (PKCG/p38) and SRc homology-2-domain-containing 
phosphatase-1 (SHP-1) overexpression49. In addition, SHP-1 
negatively regulates VEGFR2 and the insulin receptor49.
Warren et al. showed that hyperglycaemia reduces endo-
thelial VEGFR2 activity in diabetes41. ROS generation caused 
by hyperglycaemia was observed to induce VEGFR2 activation 
and its subsequent breakdown, notwithstanding the 
VEGF-A41. This would alter the normal response of endothelial 
cells to circulating VEGF-A due to lower receptor availability. 
By blocking ROS production with antioxidants, VEGFR2 avail-
ability and the lack of endothelial response to VEGF-A caused 
by hyperglycaemia were reverted41. These results suggest that 
the increase in VEGF-A present from early stages of DN may 
be secondary to “VEGF-resistance” of the VEGFR2 caused by 
higher receptor breakdown in endothelial cells.
Jointly, these publications indicate that, in DN, VEGF over-
expression in podocytes may be stimulated in an autocrine 
and paracrine way by a “VEGF-resistance” state. VEGF-A con-
nections with oxidative stress at glomerular level may repre-
sent pathways with therapeutic potential.
Relationship between angiopoietins and 
VEGF-A in DN
Angiopoietins, which are growth factors involved in angio-
genesis, have been related to DN15,36. Plasma levels of angio-
poietin 2 are high in diabetic humans and mice, thus altering 
the angiopoetin-1/angiopoetin-2 ratio. Diabetic mice with 
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recent decades. The most frequent isolated cause of CKD is 
DN. Factors related to DN development are: age over 65, 
uncontrolled hyperglycaemia, hypertension, dyslipidaemia, 
male gender, smoking habit, family history, and Hispanic 
or Afro-American origin.
2.  Glucose directly and indirectly stimulates VEGF-A cell 
expression. In DN, there is a systemic and glomerular 
increase in VEGF-A, but glomerular VEGF-A and the glomer-
ular VEGF-A/NO-eNOS relationship are key factors in DN 
pathophysiogenesis.
3.  Endothelial cells and podocytes express insulin receptors. 
Nephrin is essential for the action of the insulin receptor 
in podocytes; its activation is related to VEGF-A. VEGFR2 
and nephrin interact in podocytes. Insulin receptors, neph-
rin and VEGF-A receptors may be mechanistically related 
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in an autocrine and paracrine way by a “VEGF-resistance” 
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